Hyphens Pharma International Ltd
SGX:1J5
Hyphens Pharma International Ltd
Interest Income Expense
Hyphens Pharma International Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Interest Income Expense
-S$565k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Interest Income Expense
$10.2m
|
CAGR 3-Years
597%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Interest Income Expense
S$2.1m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-31%
|
|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Interest Income Expense
-S$3.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
Hyphens Pharma International Ltd
Glance View
Hyphens Pharma International Ltd. is an investment holding company, which engages in the provision of specialty pharmaceutical and consumer healthcare products. The firm's principal activities are those of an investment holding company and provision of management services. The firm's segments include specialty pharma principals, proprietary brands, and medical hypermart and digital. The specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position itself as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
See Also
What is Hyphens Pharma International Ltd's Interest Income Expense?
Interest Income Expense
-565k
SGD
Based on the financial report for Dec 31, 2024, Hyphens Pharma International Ltd's Interest Income Expense amounts to -565k SGD.
What is Hyphens Pharma International Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-33%
Over the last year, the Interest Income Expense growth was 30%.
You don't have any saved screeners yet